143 related articles for article (PubMed ID: 35305088)
21. Validation of NEDD8-conjugating enzyme UBC12 as a new therapeutic target in lung cancer.
Li L; Kang J; Zhang W; Cai L; Wang S; Liang Y; Jiang Y; Liu X; Zhang Y; Ruan H; Chen G; Wang M; Jia L
EBioMedicine; 2019 Jul; 45():81-91. PubMed ID: 31208947
[TBL] [Abstract][Full Text] [Related]
22. Targeting neddylation pathway with MLN4924 (Pevonedistat) induces NOXA-dependent apoptosis in renal cell carcinoma.
Wang J; Wang S; Zhang W; Wang X; Liu X; Liu L; Li L; Liang Y; Yu J; Jeong LS; Jia L; Zhao H; Zhang Y
Biochem Biophys Res Commun; 2017 Sep; 490(4):1183-1188. PubMed ID: 28669728
[TBL] [Abstract][Full Text] [Related]
23. Mutations in UBA3 confer resistance to the NEDD8-activating enzyme inhibitor MLN4924 in human leukemic cells.
Xu GW; Toth JI; da Silva SR; Paiva SL; Lukkarila JL; Hurren R; Maclean N; Sukhai MA; Bhattacharjee RN; Goard CA; Medeiros B; Gunning PT; Dhe-Paganon S; Petroski MD; Schimmer AD
PLoS One; 2014; 9(4):e93530. PubMed ID: 24691136
[TBL] [Abstract][Full Text] [Related]
24. The use of the NEDD8 inhibitor MLN4924 (Pevonedistat) in a cyclotherapy approach to protect wild-type p53 cells from MLN4924 induced toxicity.
Malhab LJ; Descamps S; Delaval B; Xirodimas DP
Sci Rep; 2016 Nov; 6():37775. PubMed ID: 27901050
[TBL] [Abstract][Full Text] [Related]
25. Targeting protein neddylation with an NEDD8-activating enzyme inhibitor MLN4924 induced apoptosis or senescence in human lymphoma cells.
Wang Y; Luo Z; Pan Y; Wang W; Zhou X; Jeong LS; Chu Y; Liu J; Jia L
Cancer Biol Ther; 2015; 16(3):420-9. PubMed ID: 25782162
[TBL] [Abstract][Full Text] [Related]
26. NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma.
Huang J; Zhou Y; Thomas GS; Gu Z; Yang Y; Xu H; Tricot G; Zhan F
Clin Cancer Res; 2015 Dec; 21(24):5532-42. PubMed ID: 26156395
[TBL] [Abstract][Full Text] [Related]
27. Neddylation: a novel modulator of the tumor microenvironment.
Zhou L; Jiang Y; Luo Q; Li L; Jia L
Mol Cancer; 2019 Apr; 18(1):77. PubMed ID: 30943988
[TBL] [Abstract][Full Text] [Related]
28. The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.
Zhou L; Chen S; Zhang Y; Kmieciak M; Leng Y; Li L; Lin H; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Rahmani M; Povirk L; Chalasani S; Berger AJ; Dai Y; Grant S
Blood; 2016 May; 127(18):2219-30. PubMed ID: 26851293
[TBL] [Abstract][Full Text] [Related]
29. Targeting Protein Neddylation for Cancer Therapy.
Zhou L; Jia L
Adv Exp Med Biol; 2020; 1217():297-315. PubMed ID: 31898235
[TBL] [Abstract][Full Text] [Related]
30. The NEDD8-activating enzyme inhibitor MLN4924 disrupts nucleotide metabolism and augments the efficacy of cytarabine.
Nawrocki ST; Kelly KR; Smith PG; Keaton M; Carraway H; Sekeres MA; Maciejewski JP; Carew JS
Clin Cancer Res; 2015 Jan; 21(2):439-47. PubMed ID: 25388161
[TBL] [Abstract][Full Text] [Related]
31. MLN4924 suppresses the BRCA1 complex and synergizes with PARP inhibition in NSCLC cells.
Guo ZP; Hu YC; Xie Y; Jin F; Song ZQ; Liu XD; Ma T; Zhou PK
Biochem Biophys Res Commun; 2017 Jan; 483(1):223-229. PubMed ID: 28034751
[TBL] [Abstract][Full Text] [Related]
32. Neural precursor cell expressed, developmentally downregulated 8‑activating enzyme inhibitor MLN4924 sensitizes colorectal cancer cells to oxaliplatin by inducing DNA damage, G2 cell cycle arrest and apoptosis.
Zheng W; Luo Z; Zhang J; Min P; Li W; Xu D; Zhang Z; Xiong P; Liang H; Liu J
Mol Med Rep; 2017 May; 15(5):2795-2801. PubMed ID: 28447739
[TBL] [Abstract][Full Text] [Related]
33. Neddylation inhibition activates the protective autophagy through NF-κB-catalase-ATF3 Axis in human esophageal cancer cells.
Liang Y; Jiang Y; Jin X; Chen P; Heng Y; Cai L; Zhang W; Li L; Jia L
Cell Commun Signal; 2020 May; 18(1):72. PubMed ID: 32398095
[TBL] [Abstract][Full Text] [Related]
34. Induction of p21-dependent senescence by an NAE inhibitor, MLN4924, as a mechanism of growth suppression.
Jia L; Li H; Sun Y
Neoplasia; 2011 Jun; 13(6):561-9. PubMed ID: 21677879
[TBL] [Abstract][Full Text] [Related]
35. Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor.
Wei D; Li H; Yu J; Sebolt JT; Zhao L; Lawrence TS; Smith PG; Morgan MA; Sun Y
Cancer Res; 2012 Jan; 72(1):282-93. PubMed ID: 22072567
[TBL] [Abstract][Full Text] [Related]
36. MLN4924 inhibits cell proliferation by targeting the activated neddylation pathway in endometrial carcinoma.
Liu H; Bei Q; Luo X
J Int Med Res; 2021 Jun; 49(6):3000605211018592. PubMed ID: 34082605
[TBL] [Abstract][Full Text] [Related]
37. Nedd8-activating enzyme inhibitor MLN4924 (Pevonedistat), inhibits miR-1303 to suppress human breast cancer cell proliferation via targeting p27
Chen Y; Du M; Yusuying S; Liu W; Tan Y; Xie P
Exp Cell Res; 2020 Jul; 392(2):112038. PubMed ID: 32360865
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of neddylation induces mitotic defects and alters MKLP1 accumulation at the midbody during cytokinesis.
Chung D; Salsman J; Dellaire G
Cell Cycle; 2019 May; 18(10):1135-1153. PubMed ID: 31057046
[TBL] [Abstract][Full Text] [Related]
39. Proteomics identifies neddylation as a potential therapy target in small intestinal neuroendocrine tumors.
Fotouhi O; Kjellin H; Juhlin CC; Pan Y; Vesterlund M; Ghaderi M; Yousef A; Andersson-Sand H; Kharaziha P; Caramuta S; Kjellman M; Zedenius J; Larsson C; Orre LM
Oncogene; 2019 Oct; 38(43):6881-6897. PubMed ID: 31406256
[TBL] [Abstract][Full Text] [Related]
40. Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924.
Jazaeri AA; Shibata E; Park J; Bryant JL; Conaway MR; Modesitt SC; Smith PG; Milhollen MA; Berger AJ; Dutta A
Mol Cancer Ther; 2013 Oct; 12(10):1958-67. PubMed ID: 23939375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
